Revolutionary Development in Aquablation Therapy
SAN JOSE, Calif. — PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a leading name in surgical robotics, has announced an exciting advancement in the world of urology. Effective January 1, 2026, Aquablation therapy has received its own Category I code. This significant leap marks a transformative period for both healthcare providers and patients alike.
Understanding the New Category I Code
The recently proposed 2026 Medicare Physician Fee Schedule introduces a new Category I Current Procedural Terminology (CPT) code for Aquablation therapy. This new code, 52XX1, is set to replace the previously used Category III CPT code 0421T, emphasizing the growing acceptance and utilization of this innovative treatment method.
Impact of Securing the Category I Code
The assignment of a Category I CPT code is not merely a technical change; it represents a vital milestone for PROCEPT and the broader urology community. As noted by Sham Shiblaq, the company’s chief commercial officer, this acknowledgment highlights the clinical effectiveness of Aquablation therapy. The transition aims to support surgeons' adoption while enhancing patient access to a treatment renowned for its durable symptom relief and minimal sexual side effects.
Payment Rates and Comparisons
As per the proposed rule, the national Medicare physician payment for the new CPT code 52XX1 is set at 16.14 total RVUs, translating to an estimated national average reimbursement of approximately $540. In a comparative context, the traditional TURP (Transurethral Resection of the Prostate) system has a slightly lower assigned value of 15.82 total RVUs, amounting to around $529. This shift illustrates the increased recognition of Aquablation therapy's value in patient care.
Timeline for Implementation
The proposed rule issued on July 14, 2025, outlines updated payment policies expected to take effect on January 1, 2026. Following this proposal, a public comment period will occur until September 2025, culminating in the final adoption of these changes likely by November 2025.
About Aquablation Therapy
Aquablation therapy stands out as the first and only ultrasound-guided, robotic-assisted treatment for benign prostatic hyperplasia (BPH). Utilizing real-time ultrasound imaging, it facilitates personalized treatment plans that cater to each patient's specific anatomical needs. This revolutionary technology allows surgeons to remove targeted prostate areas while preserving functions related to erectile and ejaculatory capabilities, alongside urinary control.
Technological Innovations
The procedure employs the AQUABEAM® robot, which ensures precise and controlled tissue ablation, delivering results that align with patients' expectations for safety and effectiveness. Its applicability is noteworthy because it accommodates varying prostate sizes and shapes, rendering it suitable for diverse cases.
PROCEPT BioRobotics Corporation: The Leader in Urological Solutions
PROCEPT BioRobotics remains committed to advancing patient care through innovative urological solutions. The company manufactures both the AQUABEAM® and the HYDROS™ Robotic Systems, with the latter being the sole AI-powered technology that administers Aquablation therapy. With BPH being a prevalent issue affecting approximately 40 million men in the United States, PROCEPT BioRobotics aims to offer efficient and effective solutions independent of a surgeon's experience. The company’s extensive clinical research, backed by over 150 peer-reviewed publications, supports the efficacy and advantages of Aquablation therapy.
Frequently Asked Questions
What is Aquablation therapy?
Aquablation therapy is a robotic-assisted, ultrasound-guided treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH) using a heat-free waterjet approach.
How does the new Category I CPT code benefit patients?
The new code enhances the recognition and reimbursement for Aquablation therapy, facilitating broader patient access to this effective treatment alternative.
What makes Aquablation therapy unique?
This therapy uniquely combines real-time imaging with robotic assistance, allowing for precise targeting and preservation of functional anatomy, which benefits patients by minimizing sexual side effects.
How does Aquablation compare with traditional methods like TURP?
Aquablation offers comparable efficacy to TURP but is designed to enhance patient safety with a reduced risk of side effects, such as sexual dysfunction.
Who is PROCEPT BioRobotics?
PROCEPT BioRobotics is an innovator in surgical robotics focused on advancing urological care through technologies like the AQUABEAM® and HYDROS™ robotic systems aimed at improving patient outcomes.
